| Literature DB >> 35600151 |
Anna Marta Pituch-Noworolska1.
Abstract
In the SARS-CoV-2 virus pandemic, the questions about specific activity of this virus in induction and/or inhibition of the innate and adaptive immune response are still open. Clinical observations of the severe and critical course of infection showed the hyperinflammation and cytokine storm. In organs and tissues that are a target for viral entry the lymphocytes and monocytes are dominant cells in tissue infiltration. There are different ways and different mechanisms leading to immune response disorders. In peripheral blood in the severe and fatal course of disease lymphopenia is frequent as a poor prognosis factor. Reduced numbers of lymphocytes, mainly T cells and NK cells, are noted in the majority of these patients. The NK cells belonging to the innate immunity system are dedicated to the antiviral response due to production of interferon (IFN) and direct lysis of virus infected cells. In SARS-CoV-2 infection NK cells' activity against this pathogen is impaired based on inhibition of IFN production and functional exhaustion. The restoration of NK cell number and function might support elimination of the SARS-CoV-2 virus, increasing chances of recovery. The use of activated NK cells in SARS-CoV-2 therapy is under clinical trials.Entities:
Keywords: ARDS; NK cells; SARS-CoV-2; exhaustion; infection; lungs; lymphopenia; stimulation
Year: 2022 PMID: 35600151 PMCID: PMC9115590 DOI: 10.5114/ceji.2022.113078
Source DB: PubMed Journal: Cent Eur J Immunol ISSN: 1426-3912 Impact factor: 1.634
SARS-CoV-2 infection – mechanisms and effects of infection on innate and adaptive immunity cells (according to ref. [2])
| Target | Mechanism | Results |
|---|---|---|
|
| ||
| Dendritic | Infection through ACE2 receptor, activation | Probably increased IFN production, reduction |
| Macrophages/monocytes | Release of IFN in initial stage of disease, later – release of proinflammatory cytokines | Decrease of CD14+CD16- monocytes, increased CD14–CD16+ monocytes subset, in lungs – increased monocytes M1-like profile associated with production of proinflammatory cytokines |
| Neutrophils | Recruitment to lungs in ARDS and thrombotic changes, expansion related to severity of symptoms | In severe cases – induction of lung injury |
| NK cells | Decreased function (exhausted profile) – reduction | Reduction of total number in severe course, |
|
| ||
| T lymphocytes | Stimulation of cellular response, activation with production of cytokines IFN, TNF and perforin, granzyme | Decrease of total T cell number, mainly decrease |
| B lymphocytes | Induction of response related to severity of disease, increase of plasmablast number in severe course | Production (not in all recovered) of neutralising specific antibodies IgG class, decreased number |
Fig. 1Mechanisms of COVID-19 infection – vascularpathophysiology as an example (according to ref. [11])
Organ infection with SARS-CoV-2 – pathological findings leading to damage and impaired function (according to ref. [2])
| Organ | Pathological findings | Clinical symptoms |
|---|---|---|
| Lungs | Mononuclear inflammatory cell infiltration, cellular and proteinaceous exudate, hyperplasia of pneumocytes (type II), vascular congestion, fibrinoid vascular necrosis, hyaline membrane formation (DAD), desquamative pneumocytes, fibrin deposit with early organization, thrombi in small vessels | ARDS, prolonged infiltration, progressing fibrosis, bronchiectases, lung insufficiency |
| Gastrointestinal | Infiltration of mucous membrane with plasma cells | Diarrhoea, nausea, vomiting in acute phase, persistent infection (viral RNA in stool) |
| Liver | Mild microvascular steatosis, mild lobular and portal infiltrates, centrilobular sinusoidal dilatation | Mild and transient liver injury (increased level of enzymes) |
| Heart | Cardiomyocytes hypertrophy, degeneration and necrosis | High risk of death due to heart attack, insufficiency of cardiovascular system |
| Kidney | Diffuse proximal tubule injuries (loss of brush border, | Acute kidney failure, proteinuria, haematuria, increase of creatinine, urea nitrogen, chronic dyselectrolytaemia |
| Brain | Typical changes for viral encephalitis in CSF | Headache, nausea, vomiting, impaired consciousness, disorders of memory after infection (“foggy mind”) |
Mechanisms of SARS-CoV-2 infection and evasion from immune system surveillance (according to ref. [1, 11])
| Target of virus | Mechanism of interaction and results |
|---|---|
| Cell surface receptors | ACE type II (ACE2), neuropilin 1 |
| Regulation of receptors | Upregulation of ACE2 by IFN type I and II, followed by shed with ADAM17 and TMPRSS2 |
| Types of cell infected | Cells expressing ACE2: lung epithelial cells, enterocytes in small intestine and colon, vascular endothelial cells, cardiac pericytes, corneal epithelial cells, renal and bladder epithelium, alveolar macrophages, hepatocytes, pancreas and others |
| Cellular outcomes after infection | Pyroptosis and cells lysis |
| Lymphocyte memory | T cells specific for common cold coronaviruses with cross reaction to SARS-CoV-2, |
| Lymphocyte disturbances | Lymphopenia and T cell functional exhaustion |
| Humoral immunity | In recovered patients – high level of anti-spike S protein antibodies with decline of level within months, in some patients – lack of specific antibodies’ production |
| Cytokine overproduction | TNF, IFN, IL-6, IL-1β, IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP-10, MCP-1 |
| Key inflammatory chemokines and attractants | CCL2, CCL3, CCL5, CCL17, CCL20, CCL22, CXCL1, CXACL2, CXCL5, CXCL8-CXCL11, |
| Clinical complications | ARDS, cardiac and kidney injuries, coagulation and neurological disorders, cytokines storm, |
ACE2 – angiotensin-converting enzyme II, TMPRSS2 – type II transmembrane serine proteases, ADAM17 – metalloproteinase domain 17
Clinical significance and prognostic role of cytokines and chemokines produced during SARS-CoV-2 infection (according to ref. [4])
| Cytokine, chemokine | Clinical significance | Prognostic value |
|---|---|---|
| IP-10, MCP-3, IL-1Ra | Associated with clinical severity and outcome in direct relation | High level – poorer prognosis |
| IL-6 | High level is associated with risk of ARDS and disease severity | High level – poorer prognosis |
| IL-8 | Direct correlation of level with severity | Highest level in ICU critical patients |
| IL-10 | Higher level than in healthy people | Without prognostic significance |
| IL-2 | Increased level in severe cases | Without prognostic significance |
| IL-2R | Related to severity, associated with high level of ferroprotein and high eosinophil count | Probably without significance |
| IL-1β | Without relation to disease severity | Without significance |
| IL-4 | Related to lung damage | No information about prognostic significance |
| IL-18 | Important in regulation of antibody production by B cells in recovery | Better prognosis |
| IFN-γ | High level is related to severity of disease | Prolonged high level – poorer prognosis |
| GM-CSF | Increased production (GM-CSF+, INF+ T cells, CD14+CD16+GM-CSF+ monocytes) is related | High level in ICU patients |
ICU – intensive care unit
Comparison of conventional and tissue resident NK cells (according to ref. [8, 9])
| NK cells conventional/ non-conventional | Characteristics | ||
|---|---|---|---|
| phenotype | production | function | |
| Conventional cNK | CD56, CD16, CD27, CD11b | Th1 cytokines: IFN-γ, TNF, GM-CSF | Cytotoxicity |
| Tissue-resident (trNK) | |||
| Thymic NK cells | CD56, CD16, CD127, CD69 | IFN-γ, TNF, FasL, chemokines | Role in thymopoiesis, elimination of double negative T cells (TRAIL) |
| Liver NK cells | CD56, CD69, CXCR6, CD49a | IFN-γ, TNF, GM-CSF, TRAIL | Low cytotoxicity, high production of inflammatory cytokines |
| Lung NK cells | CD16, CD56, | IFN-γ, TNF, GM-CSF | Cytotoxicity, support of inflammation with cytokines and chemokines |
| CD56bright, CD94, CD49a | IFN-γ, TNF | Protection of implanted fetus, promotion of placental vascularisation | |
| Uterine NK cells | Like cNK and CD69 | Cytotoxicity against melanoma cells, supporting inflammation in skin autoimmunity | |